Continence, restored.
Cobler is a clinically validated intravaginal device that gives women with urinary incontinence immediate, patient-controlled relief — without surgery, without compromise.
Get in touchUrinary incontinence is common and undertreated.
Urinary incontinence affects 1 in 3 women over their lifetime. Despite its prevalence, it remains widely undertreated — a condition shrouded in stigma, met with inadequate solutions, and rarely spoken about openly.
Current management options are limited: absorbent pads address the symptom without treating the cause; pelvic floor exercises work only for mild cases; surgery carries real risks and is often a last resort.
450,000 women in Denmark alone live with this condition. The annual cost to the EU exceeds €70 billion — two thirds of the entire cancer budget. Yet the innovation pipeline remains thin.
The anatomy of the challenge.
Stress urinary incontinence — leakage triggered by physical activity, coughing, or sneezing — is the most common form. It occurs when the urethra lacks sufficient support during increases in abdominal pressure.
Cobler works by providing targeted mechanical support at precisely the right anatomical point, restoring continence through physics rather than pharmacology or permanent structural change.
Built for women,
by women.
Designed by clinicians who understand both the anatomy and the lived experience of incontinence. Not a patch. A real solution.
Speak with the teamPrecise, immediate support
Clinically validated urinary control from the moment of insertion — no waiting, no uncertainty.
Anatomically designed
Conforms to natural anatomy for all-day comfort, allowing women to move freely and confidently.
Simple insertion and removal
Patient autonomy at the forefront — placed and removed at home, on the woman's own terms.
Evidence-based from the start.
Cobler has been developed in close collaboration with leading clinicians in urogynecology and pelvic health. Our test panel participants have reported immediate, significant improvement in continence outcomes — with no adverse effects.
The device is designed to meet the standards required for CE marking as a Class II medical device. Clinical documentation is being developed in accordance with EU MDR requirements.
We are currently seeking partnerships with clinical investigators and research institutions to advance our evidence base.